jcm-logo

Journal Browser

Journal Browser

Advances in Neuro-Oncology: Diagnostics and Treatment

A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Clinical Neurology".

Deadline for manuscript submissions: 20 March 2027 | Viewed by 267

Editors


E-Mail Website
Guest Editor
Department of Neurology, Stritch School of Medicine, Loyola University, Maywood, IL, USA
Interests: neurology; neuro-oncology; brain tumors; cancer therapies; brain metastases
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Cancer Biology, Stritch School of Medicine, Loyola University, Maywood, IL, USA
Interests: brain tumors; glioblastoma; cancer immunology and immunotherapy; neuroimmunology

Special Issue Information

Dear Colleagues,

Central nervous system tumor diagnostic and therapeutic research has gained momentum in the last decade. Despite advances in treatment, CNS tumors remain clinically challenging, with high recurrence rates and significant impact on patient neurological function and quality of life. Understanding of molecular mechanisms and the tumor microenvironment, as well as advances in diagnostics and therapeutics, has helped develop tailored treatments to improve outcomes. In clinical practice, integrating molecular biomarkers, intraoperative imaging, and novel surgical approaches has enabled more precise tumor resection and better postoperative management.

This Special Issue of the Journal of Clinical Medicine will focus on innovations in the diagnosis and treatment of central nervous system tumors. We aim to highlight clinically driven research that directly informs patient stratification, treatment selection, and long-term follow-up strategies.

We welcome the submission of original research and review articles presenting results in the above-mentioned research fields, as well as papers discussing findings of preclinical studies and clinical trials. Contributions that address clinical challenges, including advanced diagnosis technologies, rare patient treatment, and surgical treatment, are particularly encouraged.

Potential topics include (but are not limited to) the following:

Topics of interest for publication include, but are not limited to, the following:

  • Glioblastoma;
  • IDH mutant glioma;
  • Brain metastases;
  • Meningioma;
  • Glioneruonal tumors;
  • Familial tumor syndromes;
  • Tumor Embolization.

Dr. Jigisha P. Thakkar
Dr. Derek A. Wainwright
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • glioma
  • meningioma
  • brain metastases
  • blood–brain barrier

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 4444 KB  
Article
Low-Level Cerebrospinal Fluid β-hCG Elevation in Patients with Pineal Parenchymal Tumors: A Four-Case Series and Diagnostic Caution
by Yixuan He, Chuhong Tong, Yanong Li, Tao Jiang and Bo Li
J. Clin. Med. 2026, 15(18), 6934; https://doi.org/10.3390/jcm15186934 - 8 Sep 2026
Viewed by 133
Abstract
Background: Pineal region tumors (PRTs) are rare and biologically heterogeneous neoplasms with overlapping clinical and radiological features. Low-level cerebrospinal fluid (CSF) beta-human chorionic gonadotropin (β-hCG) may support a clinical diagnosis of germinoma (GE); however, its pathological specificity remains uncertain. Methods: We [...] Read more.
Background: Pineal region tumors (PRTs) are rare and biologically heterogeneous neoplasms with overlapping clinical and radiological features. Low-level cerebrospinal fluid (CSF) beta-human chorionic gonadotropin (β-hCG) may support a clinical diagnosis of germinoma (GE); however, its pathological specificity remains uncertain. Methods: We retrospectively reviewed four patients with low-level CSF β-hCG elevation whose available tissue specimens demonstrated pineal parenchymal tumors (PPTs). Tissue was obtained before systemic treatment in two patients and after platinum-based chemotherapy in two. Results: All four patients were male and aged 8 to 19 years. Pretreatment specimens from two patients demonstrated pineal parenchymal tumors of intermediate differentiation (PPTID), whereas postchemotherapy specimens from the other two demonstrated pineoblastoma (PB). Serum β-hCG was <0.1 IU/L in all patients, while CSF β-hCG ranged from 2.86 to 18.29 IU/L; serum and CSF alpha-fetoprotein (AFP) levels were normal. Two patients received platinum-based chemotherapy for presumptive intracranial germ cell tumors before tissue diagnosis, achieving stable disease or partial response. Because their specimens were obtained after chemotherapy, an occult pretreatment germ cell component could not be excluded. Conclusions: Although contemporary diagnostic protocols allow a clinical diagnosis of GE with characteristic imaging findings and low-level β-hCG elevation, isolated low-level CSF β-hCG immunoreactivity may also coexist with tissue specimens demonstrating PPT and should therefore not be considered pathognomonic for GE or interpreted in isolation. Early tissue acquisition with integrated histopathological and molecular evaluation is essential to avoid diagnostic misclassification and ensure appropriate treatment. Full article
(This article belongs to the Special Issue Advances in Neuro-Oncology: Diagnostics and Treatment)
Show Figures

Figure 1

Back to TopTop